TCR2 Therapeutics Inc

(NASDAQ:TCRR)

Latest On TCR2 Therapeutics Inc (TCRR):

Date/Time Type Description Signal Details
2023-05-11 11:08 ESTNewsTCR2 Therapeutics GAAP EPS of -$1.03 misses by $0.34N/A
2023-04-22 00:58 ESTNewsAdaptimmune Shareholders Can Lock In A Big Merger Spread By Swapping To TCR2 TherapeuticsN/A
2023-04-19 03:39 ESTNewsAdaptimmune, TCR2 Therapeutics set May 30 for shareholder votes on dealN/A
2023-03-23 08:39 ESTNewsTCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74N/A
2023-03-06 19:50 ESTNewsTCR² Therapeutics stock rise 41% after merger deal with AdaptimmuneN/A
2023-02-15 16:22 ESTNewsTCR² Therapeutics: Refocused Pipeline Puts It On A Solid PathN/A
2022-11-08 19:52 ESTNewsTCR2 Therapeutics GAAP EPS of -$0.79 beats by $0.06N/A
2022-09-28 09:08 ESTNewsTCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trialN/A
2022-08-19 02:11 ESTNewsTCR² Therapeutics: Betting On A Solid ReversalN/A
2022-08-08 09:01 ESTNewsTCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02N/A
2022-06-27 16:43 ESTNewsTCR² Therapeutics appoints Eric Sullivan as CFON/A
2022-05-13 01:32 ESTNewsTCR2 Therapeutics GAAP EPS of -$0.76 misses by $0.01N/A
2022-03-23 14:46 ESTNewsTCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04N/A
2022-01-19 18:29 ESTNewsArvinas, Arrowhead win Buy ratings as Goldman Sachs starts coverage on platform biotechsN/A
2022-01-06 03:12 ESTNewsTCR2 Therapeutics: Trading Below CashN/A
2021-11-10 16:48 ESTNewsTCR2 Therapeutics EPS misses by $0.02N/A
2021-11-03 00:18 ESTNewsWarning: TCRR is at high risk of performing badlyN/A
2021-10-26 02:43 ESTNewsTCR2 Therapeutics inks collaboration agreement with Bristol Myers SquibbN/A
2021-10-13 09:02 ESTNewsTCR2 Therapeutics: Trading Near Cash ValueN/A
2021-09-28 02:56 ESTNewsTCR2 Therapeutics (TCRR) Investor PresentationN/A
2021-09-28 02:56 ESTNewsTcr2 Therapeutics (TCRR) presents Interim Data from Ongoing Gavo-cel Phase 1/2 Clinical TrialN/A
2021-09-22 07:45 ESTNewsABCL, TCRR, KYMR and GRTS among after hours moversN/A
2021-09-22 07:44 ESTNewsTCR Therapeutics shares fall 31% on interim results from early-stage gavo-cel cancer studyN/A
2021-09-22 07:43 ESTNewsTCR2 Therapeutics reaches 15 month low as Wedbush downgrade on tumor trial dataN/A
2021-09-03 03:18 ESTNewsTCR Therapeutics gets FDA Orphan Drug status for gavo-cel cholangiocarcinoma treatmentN/A
2021-07-22 03:40 ESTNewsTCR2 Therapeutics - Promising Technology And Upside PotentialN/A
2021-07-22 03:09 ESTNewsTCR2 Therapeutics appoints Peter Olagunju as CTON/A
2021-04-16 20:21 ESTNewsTCR2 Therapeutics (TCRR) Investor Presentation - SlideshowN/A
2021-03-16 22:10 ESTAnalyst RatingThe Analyst Target Price has increased from $45.44 to $45.67.Buy
2021-03-12 20:51 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 12:36 ESTAnalyst RatingThe Analyst Target Price has increased from $44.63 to $45.44.Buy
2021-03-12 12:36 ESTEarnings EstimateAn EPS average of -$2.93 is estimated for the 2022 year.Sell
2021-03-12 12:36 ESTEarnings EstimateAn EPS average of -$0.52 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 15:10 ESTNewsTCR2 Therapeutics EPS beats by $0.02N/A
2021-01-21 12:53 ESTAnalyst RatingThe Analyst Target Price has decreased from $46.89 to $44.63.Neutral
2021-01-20 08:33 ESTNewsTCR² Therapeutics prices $140M stock offeringN/A
2021-01-19 18:14 ESTNewsTCR² Therapeutics to raise $125M capitalN/A
2021-01-19 18:13 ESTNewsTCR2 Therapeutics proposes public offeringN/A
2021-01-08 23:12 ESTNewsTCR2 Therapeutics provides 2021 data and regulatory milestonesN/A
2020-12-16 13:10 ESTAnalyst RatingThe Analyst Target Price has increased from $44.78 to $46.89.Buy
2020-12-15 13:06 ESTAnalyst RatingThe Analyst Target Price has increased from $35.56 to $44.78.Buy
2020-12-01 13:16 ESTAnalyst RatingThe Analyst Target Price has increased from $35.22 to $35.56.Buy
2020-11-26 21:44 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 12:54 ESTAnalyst RatingThe Analyst Target Price has increased from $35.11 to $35.22.Buy
2020-11-17 05:31 ESTAnalyst RatingThe Analyst Target Price has increased from $34.78 to $35.11.Buy
2020-11-13 21:38 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:29 ESTAnalyst RatingThe Analyst Target Price has increased from $33.78 to $34.78.Buy
2020-11-13 13:29 ESTEarnings EstimateAn EPS average of -$0.56 is estimated for the quarter ending on March 31, 2021.N/A
2020-11-13 10:59 ESTNewsTCR2 Therapeutics reports Q3 resultsN/A
2020-11-11 01:53 ESTNewsTCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacityN/A

About TCR2 Therapeutics Inc (TCRR):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

TCRR Quotes by TradingView

See Advanced Chart

General

  • Name TCR2 Therapeutics Inc
  • Symbol TCRR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2019-02-14
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.tcr2.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 4.22
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.33
  • Next Year EPS Estimate -$2.85
  • Next Quarter EPS Estimate -$0.56
  • Return on Assets -21%
  • Return on Equity -34%
  • Earnings Per Share -$10.67
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 937.23 million
  • EBITDA -37915000
  • Analyst Target Price $45.67
  • Book Value Per Share $7.06
View More

Share Statistics

  • Shares Outstanding 38.14 million
  • Shares Float 23.93 million
  • % Held by Insiders 157%
  • % Held by Institutions 96.72%
  • Shares Short 3.1 million
  • Shares Short Prior Month 3.12 million
  • Short Ratio 7.44
  • Short % of Float 10%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 2.17
  • 52 Week High $35.86
  • 52 Week Low $5.89
  • 50 Day Moving Average 27.05
  • 200 Day Moving Average 25.38
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

TCR2 Therapeutics Inc (TCRR) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

TCR2 Therapeutics Inc (TCRR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.48-$0.490.47%
2020-09-302020-11-12$N/A-$0.49-$0.49-0.95%
2020-06-302020-08-12$N/A-$0.59-$0.59-0.68%
2020-03-312020-05-14$N/A-$0.56-$0.53-5.7%
2019-12-312020-03-30$N/A-$0.45-$0.5822.57%
2019-09-302019-11-12$N/A-$0.49-$0.49-0.82%
2019-06-302019-08-08$N/A-$0.40-$0.423.83%
2019-03-312019-05-13$N/A-$2.47-$0.35-605.71%
2018-12-312019-03-29$N/A-$1.06-$1.7037.84%

TCR2 Therapeutics Inc (TCRR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

TCR2 Therapeutics Inc (TCRR) Chart:

TCR2 Therapeutics Inc (TCRR) News:

Below you will find a list of latest news for TCR2 Therapeutics Inc (TCRR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

TCR2 Therapeutics Inc (TCRR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest TCRR Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$2.565
Jun 13, 2022 7:59 PM EST35$2.565
Jun 13, 2022 7:59 PM EST3$2.565
Jun 13, 2022 7:59 PM EST7$2.565
Jun 13, 2022 7:59 PM EST10$2.55

TCR2 Therapeutics Inc (TCRR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1750019/000156459020025260/0001564590-20-025260-index.htm
2018-10-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1750019/000000000018031306/0000000000-18-031306-index.htm
2018-10-23UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1750019/000000000018033200/0000000000-18-033200-index.htm
2019-01-31UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1750019/000000000019000534/0000000000-19-000534-index.htm
2020-03-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1750019/000000000020002260/0000000000-20-002260-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003480/0000899243-19-003480-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003482/0000899243-19-003482-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003483/0000899243-19-003483-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003484/0000899243-19-003484-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003485/0000899243-19-003485-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003490/0000899243-19-003490-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003491/0000899243-19-003491-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003492/0000899243-19-003492-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003496/0000899243-19-003496-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003497/0000899243-19-003497-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319003499/0000899243-19-003499-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319004393/0000899243-19-004393-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319004395/0000899243-19-004395-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319004398/0000899243-19-004398-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319004404/0000899243-19-004404-index.htm
2019-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/0000899243-19-025909-index.htm
2019-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029791/0000899243-19-029791-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029838/0000899243-19-029838-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029852/0000899243-19-029852-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029858/0000899243-19-029858-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029860/0000899243-19-029860-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029861/0000899243-19-029861-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319029863/0000899243-19-029863-index.htm
2019-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000089924319030063/0000899243-19-030063-index.htm
2018-09-07DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1750019/000095012318009342/0000950123-18-009342-index.htm
2018-09-13DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1750019/000095012318009413/0000950123-18-009413-index.htm
2018-10-10DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1750019/000095012318009813/0000950123-18-009813-index.htm
2018-10-10DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1750019/000095012318009815/0000950123-18-009815-index.htm
2018-10-25DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1750019/000095012318010154/0000950123-18-010154-index.htm
2018-10-25DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1750019/000095012318010155/0000950123-18-010155-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1750019/000110465920012805/0001104659-20-012805-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1750019/000110465920021831/0001104659-20-021831-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000114420419007371/0001144204-19-007371-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000114420419009312/0001144204-19-009312-index.htm
2019-02-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1750019/000114420419009313/0001144204-19-009313-index.htm
2019-02-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1750019/000114420419009412/0001144204-19-009412-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1750019/000117266120000907/0001172661-20-000907-index.htm
2018-12-28S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1750019/000119312518360714/0001193125-18-360714-index.htm
2019-01-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1750019/000119312519001382/0001193125-19-001382-index.htm
2019-02-01S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1750019/000119312519025782/0001193125-19-025782-index.htm
2019-02-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1750019/000119312519025794/0001193125-19-025794-index.htm
2019-02-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1750019/000119312519033938/0001193125-19-033938-index.htm
2019-02-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1750019/000119312519033950/0001193125-19-033950-index.htm
2019-02-128-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1750019/000119312519035883/0001193125-19-035883-index.htm
2019-02-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1750019/000119312519037835/0001193125-19-037835-index.htm
2019-02-13FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1750019/000119312519038130/0001193125-19-038130-index.htm
2019-02-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1750019/000119312519041159/0001193125-19-041159-index.htm
2019-02-15424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1750019/000119312519042430/0001193125-19-042430-index.htm
2019-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000119312519049863/0001193125-19-049863-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000119312519052064/0001193125-19-052064-index.htm
2019-03-04SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1750019/000119312519062378/0001193125-19-062378-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000119312519268891/0001193125-19-268891-index.htm
2020-01-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1750019/000119312520018606/0001193125-20-018606-index.htm
2020-03-06S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1750019/000119312520065218/0001193125-20-065218-index.htm
2020-03-30S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1750019/000119312520090086/0001193125-20-090086-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1750019/000119312520091059/0001193125-20-091059-index.htm
2020-04-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1750019/000119312520119029/0001193125-20-119029-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000119312520199118/0001193125-20-199118-index.htm
2020-07-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1750019/000119312520199694/0001193125-20-199694-index.htm
2020-07-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1750019/000119312520202547/0001193125-20-202547-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000119312520206368/0001193125-20-206368-index.htm
2020-08-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1750019/000119312520220330/0001193125-20-220330-index.htm
2020-08-14DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1750019/000119312520220342/0001193125-20-220342-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000119312520261966/0001193125-20-261966-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919119009857/0001209191-19-009857-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919119009858/0001209191-19-009858-index.htm
2019-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919119009859/0001209191-19-009859-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919119012243/0001209191-19-012243-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919119012245/0001209191-19-012245-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919119012247/0001209191-19-012247-index.htm
2020-03-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120021376/0001209191-20-021376-index.htm
2020-03-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120021379/0001209191-20-021379-index.htm
2020-03-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120021382/0001209191-20-021382-index.htm
2020-03-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm
2020-03-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120021424/0001209191-20-021424-index.htm
2020-04-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120024475/0001209191-20-024475-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120024480/0001209191-20-024480-index.htm
2020-05-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120026850/0001209191-20-026850-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120026858/0001209191-20-026858-index.htm
2020-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000120919120056390/0001209191-20-056390-index.htm
2019-02-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1750019/000135445719000070/0001354457-19-000070-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000156459019042589/0001564590-19-042589-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1750019/000156459019042612/0001564590-19-042612-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000156459020013845/0001564590-20-013845-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1750019/000156459020013856/0001564590-20-013856-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000156459020016805/0001564590-20-016805-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000156459020020618/0001564590-20-020618-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000156459020025252/0001564590-20-025252-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1750019/000156459020025260/0001564590-20-025260-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000156459020039478/0001564590-20-039478-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1750019/000156459020039480/0001564590-20-039480-index.htm
2019-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1750019/000175001919000009/0001750019-19-000009-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000013/0001750019-19-000013-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000021/0001750019-19-000021-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000022/0001750019-19-000022-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000023/0001750019-19-000023-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000024/0001750019-19-000024-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000025/0001750019-19-000025-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000026/0001750019-19-000026-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000027/0001750019-19-000027-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000035/0001750019-19-000035-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1750019/000175001919000036/0001750019-19-000036-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000044/0001750019-19-000044-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1750019/000175001919000046/0001750019-19-000046-index.htm
2019-08-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000051/0001750019-19-000051-index.htm
2019-08-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1750019/000175001919000053/0001750019-19-000053-index.htm
2019-02-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1750019/999999999519000215/9999999995-19-000215-index.htm
2020-04-28EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1750019/999999999520000897/9999999995-20-000897-index.htm
2019-02-14CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1750019/999999999719000307/9999999997-19-000307-index.htm

TCR2 Therapeutics Inc (TCRR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of TCR2 Therapeutics Inc (TCRR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 157%
Institutional Ownership: 9672%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-20Neil W GibsonDirectorSell648.007.945,145.120.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm
2019-09-04Morana Jovan-Embiricos10% Share HolderSell12,214.0017.55214,414.33102,563.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-09-03Morana Jovan-Embiricos10% Share HolderSell10,559.0017.01179,652.94114,777.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-08-29Morana Jovan-Embiricos10% Share HolderSell3,700.0017.0162,925.16125,336.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-08-28Morana Jovan-Embiricos10% Share HolderSell6,700.0017.01113,940.87129,036.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-12-11Morana Jovan-Embiricos10% Share HolderSell4,153.0017.6573,310.831,299,876.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-10Morana Jovan-Embiricos10% Share HolderSell30,475.0017.62537,067.021,304,029.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-09Morana Jovan-Embiricos10% Share HolderSell75,067.0017.651,325,015.121,334,504.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-08-27Morana Jovan-Embiricos10% Share HolderSell1,200.0017.0120,413.56135,736.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-08-26Morana Jovan-Embiricos10% Share HolderSell29,128.0017.01495,478.93136,936.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-10-22Morana Jovan-Embiricos10% Share HolderSell2,085.0015.1631,602.551,409,571.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/0000899243-19-025909-index.htm
2019-09-23Morana Jovan-Embiricos10% Share HolderSell5,516.0017.3195,489.681,411,656.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-09-20Morana Jovan-Embiricos10% Share HolderSell197,343.0017.943,539,425.641,417,172.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-12-19Morana Jovan-Embiricos10% Share HolderSell35,323.0016.47581,819.26155,986.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319029791/0000899243-19-029791-index.htm
2019-02-19ANSBERT GADICKEDirectorBuy1,373,333.0015.0020,599,995.001,569,235.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319004395/0000899243-19-004395-index.htm
2019-08-23Morana Jovan-Embiricos10% Share HolderSell3.0017.0051.00166,064.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-08-22Morana Jovan-Embiricos10% Share HolderSell100.0017.031,703.00166,067.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-08-21Morana Jovan-Embiricos10% Share HolderSell500.0017.008,500.00166,167.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319022834/0000899243-19-022834-index.htm
2019-08-30Mayur Ian SomaiyaChief Financial OfficerBuy1,666.0012.7521,241.501,666.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021376/0001209191-20-021376-index.htm
2019-02-19Morana Jovan-EmbiricosDirectorBuy166,667.0015.002,500,005.00166,667.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319004404/0000899243-19-004404-index.htm
2019-09-23Morana Jovan-Embiricos10% Share HolderSell683.0017.3111,823.69174,871.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-09-20Morana Jovan-Embiricos10% Share HolderSell24,446.0017.94438,448.79175,554.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-12-18Morana Jovan-Embiricos10% Share HolderSell2,433.0017.0141,375.60191,309.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319029791/0000899243-19-029791-index.htm
2020-02-28Alfonso Quintas CardamaChief Medical OfficerBuy1,082.0010.1010,928.201,925.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021379/0001209191-20-021379-index.htm
2019-02-19Morana Jovan-EmbiricosDirectorBuy200,000.0015.003,000,000.00200,000.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319004404/0000899243-19-004404-index.htm
2019-02-19Investment Ltd Upnorth10% Share HolderBuy200,000.0015.003,000,000.002,137,419.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319004398/0000899243-19-004398-index.htm
2020-02-28Garry E MenzelPresident & CEOBuy1,287.0010.1012,998.702,267.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021382/0001209191-20-021382-index.htm
2020-03-13Neil W GibsonDirectorSell52,000.006.52338,894.4027,640.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm
2020-02-28Mayur Ian SomaiyaChief Financial OfficerBuy1,473.0010.1014,877.303,139.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021376/0001209191-20-021376-index.htm
2019-12-11Morana Jovan-Embiricos10% Share HolderSell1,054.0017.6518,605.74330,238.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-10Morana Jovan-Embiricos10% Share HolderSell7,741.0017.62136,421.19331,292.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-02-19Oncology Impact Fund L.P. UBS10% Share HolderBuy666,667.0015.0010,000,005.003,370,982.00https://www.sec.gov/Archives/edgar/data/1750019/000120919119012247/0001209191-19-012247-index.htm
2019-12-09Morana Jovan-Embiricos10% Share HolderSell19,070.0017.65336,606.48339,033.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-23Patrick BaeuerleDirectorSell84,907.0015.441,310,964.08350,786.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319030063/0000899243-19-030063-index.htm
2019-10-22Morana Jovan-Embiricos10% Share HolderSell530.0015.168,033.26358,103.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/0000899243-19-025909-index.htm
2019-09-23Morana Jovan-Embiricos10% Share HolderSell1,401.0017.3124,253.27358,633.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-09-20Morana Jovan-Embiricos10% Share HolderSell50,134.0017.94899,173.34360,034.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-12-11Morana Jovan-Embiricos10% Share HolderSell1,155.0017.6520,388.64361,665.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-10Morana Jovan-Embiricos10% Share HolderSell8,479.0017.62149,427.11362,820.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-09Morana Jovan-Embiricos10% Share HolderSell20,886.0017.65368,660.87371,299.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2020-03-18Neil W GibsonDirectorSell3,120.006.8321,309.603,788.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm
2020-10-29Robert HofmeisterChief Science OfficerSell20,000.0019.10382,000.0038,850.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120056390/0001209191-20-056390-index.htm
2019-10-22Morana Jovan-Embiricos10% Share HolderSell580.0015.168,791.12392,185.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/0000899243-19-025909-index.htm
2019-09-23Morana Jovan-Embiricos10% Share HolderSell1,535.0017.3126,573.00392,765.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-09-20Morana Jovan-Embiricos10% Share HolderSell54,907.0017.94984,779.01394,300.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-02-19MPM BioVentures 2014, L.P.10% Share HolderBuy706,666.0015.0010,599,990.004,050,865.00https://www.sec.gov/Archives/edgar/data/1750019/000120919119012243/0001209191-19-012243-index.htm
2019-02-19MPM SunStates Fund, L.P.10% Share HolderBuy706,666.0015.0010,599,990.004,050,865.00https://www.sec.gov/Archives/edgar/data/1750019/000120919119012245/0001209191-19-012245-index.htm
2019-12-11Morana Jovan-Embiricos10% Share HolderSell1,381.0017.6524,378.10432,319.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-10Morana Jovan-Embiricos10% Share HolderSell10,135.0017.62178,611.13433,700.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-12-20Patrick BaeuerleDirectorSell32,022.0015.16485,453.52435,693.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319030063/0000899243-19-030063-index.htm
2019-12-09Morana Jovan-Embiricos10% Share HolderSell24,966.0017.65440,677.36443,835.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/0000899243-19-028968-index.htm
2019-02-19Morana Jovan-EmbiricosDirectorBuy166,667.0015.002,500,005.00449,207.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319004404/0000899243-19-004404-index.htm
2019-09-23Morana Jovan-Embiricos10% Share HolderSell1,835.0017.3131,766.42469,464.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-09-20Morana Jovan-Embiricos10% Share HolderSell65,633.0017.941,177,154.11471,299.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-02-19Morana Jovan-EmbiricosDirectorBuy133,333.0015.001,999,995.00536,962.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319004404/0000899243-19-004404-index.htm
2020-10-29Robert HofmeisterChief Science OfficerBuy20,000.000.7414,800.0058,850.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120056390/0001209191-20-056390-index.htm
2020-03-19Neil W GibsonDirectorSell3,140.007.4123,267.40648.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm
2020-03-17Neil W GibsonDirectorSell3,009.006.4919,528.416,908.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm
2019-12-19Morana Jovan-Embiricos10% Share HolderSell6,642.0016.47109,403.0482,575.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319029791/0000899243-19-029791-index.htm
2019-08-30Alfonso Quintas CardamaChief Medical OfficerBuy843.0012.7510,748.25843.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021379/0001209191-20-021379-index.htm
2019-12-18Morana Jovan-Embiricos10% Share HolderSell458.0017.017,788.7589,217.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319029791/0000899243-19-029791-index.htm
2019-09-23Morana Jovan-Embiricos10% Share HolderSell351.0017.316,076.3089,675.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-09-20Morana Jovan-Embiricos10% Share HolderSell12,537.0017.94224,856.1190,026.00https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/0000899243-19-024208-index.htm
2019-08-30Garry E MenzelPresident & CEOBuy980.0012.7512,495.00980.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021382/0001209191-20-021382-index.htm
2020-03-16Neil W GibsonDirectorSell17,723.006.60117,042.699,917.00https://www.sec.gov/Archives/edgar/data/1750019/000120919120021385/0001209191-20-021385-index.htm